CHEK2 and ovarian cancer: A multi-ethnic population-based study of a cohort of breast cancer and ovarian cancer patients found that for breast cancer 2.3% (95% CI 1.8% to 2.8%) of white individuals and only 0.15% (95% CI 0% to 0.82%) of black individuals carried a pathogenic CHEK2 variant39.